MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 157 filers reported holding MERSANA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9,967 | +9.4% | 3,029,555 | +36.7% | 0.31% | -42.9% |
| Q1 2023 | $9,107 | -29.4% | 2,215,788 | +0.7% | 0.54% | -24.9% |
| Q4 2022 | $12,892 | -99.9% | 2,200,000 | 0.0% | 0.72% | +13.4% |
| Q3 2022 | $14,872,000 | +46.3% | 2,200,000 | 0.0% | 0.64% | +16.9% |
| Q2 2022 | $10,164,000 | +15.8% | 2,200,000 | 0.0% | 0.54% | +47.6% |
| Q1 2022 | $8,778,000 | +17.6% | 2,200,000 | +83.3% | 0.37% | +81.3% |
| Q4 2021 | $7,464,000 | -34.0% | 1,200,000 | 0.0% | 0.20% | -19.8% |
| Q3 2021 | $11,316,000 | -30.6% | 1,200,000 | 0.0% | 0.25% | -23.6% |
| Q2 2021 | $16,296,000 | -16.1% | 1,200,000 | 0.0% | 0.33% | -3.5% |
| Q1 2021 | $19,416,000 | -39.2% | 1,200,000 | 0.0% | 0.34% | -50.0% |
| Q4 2020 | $31,932,000 | +71.5% | 1,200,000 | +20.0% | 0.69% | +51.8% |
| Q3 2020 | $18,620,000 | -0.5% | 1,000,000 | +25.0% | 0.45% | -13.7% |
| Q2 2020 | $18,720,000 | – | 800,000 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 5,000,000 | $6,350,000 | 1.92% |
| VR Adviser, LLC | 11,328,000 | $14,386,560 | 1.51% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $11,002,865 | 1.23% |
| Affinity Asset Advisors, LLC | 2,850,000 | $3,619,500 | 1.02% |
| EcoR1 Capital, LLC | 19,364,688 | $24,593,154 | 0.83% |
| Altium Capital Management LP | 1,059,136 | $1,345,103 | 0.70% |
| 5AM Venture Management, LLC | 1,305,000 | $1,657,350 | 0.48% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $1,148,420 | 0.38% |
| COMMODORE CAPITAL LP | 2,244,378 | $2,850,360 | 0.33% |
| Philosophy Capital Management LLC | 2,342,634 | $2,975,145 | 0.32% |